Expression of the beta-chemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissue.
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS) characterised by perivascular inflammatory cell infiltrates and plaques of demyelination. Chemokines have been shown to play an important role in the activation and directional migration of cells to sites of CNS inflammation. The action of chemokines requires the expression of their complementary chemokine receptors by their target cells. We have examined the expression of the beta-chemokine receptors CCR2, CCR3 and CCR5 in post-mortem MS CNS tissue using single- and double-labelling immunocytochemistry techniques. Low levels of CCR2, CCR3 and CCR5 were expressed by microglial cells throughout control CNS tissue. In chronic active MS lesions CCR2, CCR3 and CCR5 were associated with foamy macrophages and activated microglia. CCR2 and CCR5 were also present on large numbers of infiltrating lymphocytes. A smaller number of CCR3-positive lymphocytes were present, but we also noted CCR3 and CCR5 on astrocytes in five of the 14 cases of MS investigated, particularly associated with processes around vessels and at the glia limitans. Ligands for CCR2 and CCR3 include MCP-1 and MCP-3 which were co-localised around vessels with the infiltrating leukocytes, but were also present in unaffected areas of cortex. The elevated expression of CCR2, CCR3 and CCR5 in the CNS in MS suggests these beta-chemokine receptors and their ligands play a role in the pathogenesis of MS.
Simpson
J
J
Biomedical Research Centre and Division of Biomedical Sciences, Sheffield Hallam University, City Campus, Pond Street, South Yorkshire, S1 1WB, Sheffield, UK.
Rezaie
P
P
Newcombe
J
J
Cuzner
M L
ML
Male
D
D
Woodroofe
M N
MN
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000918:Antibody Specificity; D001253:Astrocytes / Q000378:metabolism / Q000473:pathology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D002490:Central Nervous System / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D018932:Chemokine CCL2 / Q000032:analysis; D054410:Chemokine CCL7; D002634:Chemotaxis, Leukocyte; D002908:Chronic Disease; D016207:Cytokines; D018450:Disease Progression; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007249:Inflammation / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D008024:Ligands; D008264:Macrophages / Q000276:immunology / Q000378:metabolism; D008297:Male; D016555:Matched-Pair Analysis; D017628:Microglia / Q000378:metabolism / Q000473:pathology; D008875:Middle Aged; D018945:Monocyte Chemoattractant Proteins / Q000032:analysis; D009103:Multiple Sclerosis / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D054390:Receptors, CCR2; D054397:Receptors, CCR3; D019713:Receptors, CCR5 / Q000032:analysis*; D019707:Receptors, Chemokine / Q000032:analysis*; D012008:Recurrence
C515450:CCL7 protein, human; C515334:CCR2 protein, human; C515350:CCR3 protein, human; D018932:Chemokine CCL2; D054410:Chemokine CCL7; D016207:Cytokines; D008024:Ligands; D018945:Monocyte Chemoattractant Proteins; D054390:Receptors, CCR2; D054397:Receptors, CCR3; D019713:Receptors, CCR5; D019707:Receptors, Chemokine